MGC Pharmaceuticals Ltd's (ASX:MXC) (FRA:H5O) (LON:MXC) co-founder and MD Roby Zomer talks to Proactive London's Katie Pilbeam about their cannabis-derived epilepsy product CannEpil which has been added to the Primary Care Reimbursement Service (PCRS) in Ireland.
This means the treatment will be free of charge for patients prescribed the treatment.
This subsidy decision follows an earlier approval for CannEpil, secured in December last year, which greenlit the product’s distribution and prescription in Ireland.